Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Haworth

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Viruses|February 11, 2016
To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic VirusesKevin A Cassady, Kellie B Haworth, Josh Jackson, et al.
Journal of Environmental Management|February 25, 2020
Managing multifunctional landscapes: Local insights from a Pacific Island Country contextJ M A Duncan, B Haworth, B Boruff, et al.
Acta Neurologica Scandinavica|February 5, 2000
The electroencephalogram in dementia with Lewy bodiesP A Barber, A R Varma, J J Lloyd, et al.
Pediatric Blood & Cancer|July 18, 2018
Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimensMary Frances Wedekind, Kellie B Haworth, Michael Arnold, et al.
Pediatric Blood & Cancer|December 20, 2014
Going back to class I: MHC and immunotherapies for childhood cancerKellie B Haworth, Jennifer L Leddon, Chun-Yu Chen, et al.
Biochemistry|August 17, 2005
Interplay of isoprenoid and peptide substrate specificity in protein farnesyltransferaseSarah A Reigard, Todd J Zahn, Kellie B Haworth, et al.
Molecular Therapy Oncolytics|June 27, 2017
Oncolytic Herpes Virus rRp450 Shows Efficacy in Orthotopic Xenograft Group 3/4 Medulloblastomas and Atypical Teratoid/Rhabdoid TumorsAdam W Studebaker, Brian J Hutzen, Christopher R Pierson, et al.
Oncotarget|November 16, 2017
Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapyKellie B Haworth, Michael A Arnold, Christopher R Pierson, et al.
Pediatric Blood & Cancer|November 18, 2015
Characterization of MHC Class I and β-2-Microglobulin Expression in Pediatric Solid Malignancies to Guide Selection of Immune-Based Therapeutic TrialsKellie B Haworth, Michael A Arnold, Christopher R Pierson, et al.
Molecular Therapy Oncolytics|October 6, 2015
Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in childrenTimothy P Cripe, Chun-Yu Chen, Nicholas L Denton, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Viruses|February 11, 2016
To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic VirusesKevin A Cassady, Kellie B Haworth, Josh Jackson, et al.
Journal of Environmental Management|February 25, 2020
Managing multifunctional landscapes: Local insights from a Pacific Island Country contextJ M A Duncan, B Haworth, B Boruff, et al.
Acta Neurologica Scandinavica|February 5, 2000
The electroencephalogram in dementia with Lewy bodiesP A Barber, A R Varma, J J Lloyd, et al.
Pediatric Blood & Cancer|July 18, 2018
Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimensMary Frances Wedekind, Kellie B Haworth, Michael Arnold, et al.
Pediatric Blood & Cancer|December 20, 2014
Going back to class I: MHC and immunotherapies for childhood cancerKellie B Haworth, Jennifer L Leddon, Chun-Yu Chen, et al.
Biochemistry|August 17, 2005
Interplay of isoprenoid and peptide substrate specificity in protein farnesyltransferaseSarah A Reigard, Todd J Zahn, Kellie B Haworth, et al.
Molecular Therapy Oncolytics|June 27, 2017
Oncolytic Herpes Virus rRp450 Shows Efficacy in Orthotopic Xenograft Group 3/4 Medulloblastomas and Atypical Teratoid/Rhabdoid TumorsAdam W Studebaker, Brian J Hutzen, Christopher R Pierson, et al.
Oncotarget|November 16, 2017
Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapyKellie B Haworth, Michael A Arnold, Christopher R Pierson, et al.
Pediatric Blood & Cancer|November 18, 2015
Characterization of MHC Class I and β-2-Microglobulin Expression in Pediatric Solid Malignancies to Guide Selection of Immune-Based Therapeutic TrialsKellie B Haworth, Michael A Arnold, Christopher R Pierson, et al.
Molecular Therapy Oncolytics|October 6, 2015
Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in childrenTimothy P Cripe, Chun-Yu Chen, Nicholas L Denton, et al.
Pageof 2